Thymosin alpha-1 (Tα1) is a 28-amino acid peptide fragment derived from the larger precursor protein prothymosin alpha. It was first isolated from bovine thymus tissue in the 1970s and identified as a key immunomodulatory agent produced by the thymic epithelial cells. The peptide plays a crucial role in the maturation and differentiation of T-lymphocytes, particularly the CD4+ and CD8+ T-cell subsets, and is considered a primary biological response modifier. Its significance lies in its ability to restore immune function in states of immunodeficiency, making it a subject of extensive research in immunology, oncology, and infectious diseases. The synthetic version, thymalfasin, is identical to the endogenous peptide and has been developed as a therapeutic agent.
Quick Facts
| Also Known As | Tα1, Thymalfasin, Zadaxin |
|---|---|
| Sequence | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH |
| Molecular Formula | C₁₂₉H₂₁₅N₃₃O₅₅ |
| Molecular Weight | 3108.3 Da |
Research Parameters
| Half-Life | ~2 hours |
|---|---|
| Stability | Lyophilized powder is stable for at least 24 months when stored at -20°C. After reconstitution in bacteriostatic water, the solution is typically stable for up to 28 days when stored at 2-8°C (refrigerated). |
| Solubility | Bacteriostatic Water (0.9% Benzyl Alcohol) or Sterile Water for Injection |
| Vial Size | 1 mg |
| Storage (Lyophilized) | -20°C, protect from light and moisture |
| Storage (Reconstituted) | 2-8°C (refrigerated), protected from light. Do not freeze. |
| Typical Research Dose | 900-1600 mcg |
| Cycle Parameters | Common research protocols involve subcutaneous injection twice per week. Some studies use a daily induction phase for 2-4 weeks followed by a twice-weekly maintenance phase, often continued for several months depending on the research model. |
| Amino Acid Count | 30 |
Mechanism of Action
Thymosin alpha-1 exerts its immunomodulatory effects through multiple interconnected pathways, primarily by enhancing T-cell function and modulating cytokine production. It acts on both innate and adaptive immune systems.
Toll-like Receptor (TLR) Signaling: Tα1 can bind to and modulate signaling through Toll-like receptors (particularly TLR9), leading to the activation of myeloid differentiation primary response 88 (MyD88) and subsequent nuclear factor kappa B (NF-κB) translocation. This promotes the production of pro-inflammatory cytokines and enhances dendritic cell maturation.
T-cell Differentiation and Maturation: The peptide promotes the maturation of thymocytes into functional T-cells within the thymus. It upregulates the expression of T-cell surface markers (CD3, CD4, CD8) and increases the production of T-cell growth factors like interleukin-2 (IL-2). It also enhances the activity of Th1 cells, which are critical for cell-mediated immunity.
Cytokine Modulation: Tα1 shifts the cytokine balance towards a Th1 profile. It increases the production of interferon-gamma (IFN-γ), interleukin-12 (IL-12), and tumor necrosis factor-alpha (TNF-α), while it can downregulate Th2-associated cytokines like IL-4 and IL-10 under certain conditions. This modulation is crucial for effective antiviral and antitumor responses.
Apoptosis Regulation: The peptide can inhibit apoptosis in T-lymphocytes, particularly under conditions of stress or immune suppression, thereby helping to maintain a robust lymphocyte population.
Research Applications
Immunodeficiency Disorders: Research has demonstrated Tα1's efficacy in restoring immune function in primary and secondary immunodeficiencies. Studies in animal models and clinical trials show it can increase CD4+ T-cell counts, improve lymphocyte proliferation responses, and reduce the frequency of opportunistic infections.
Oncology (as an adjuvant): In cancer research, Tα1 is investigated as an immunoadjuvant to enhance the efficacy of vaccines and conventional therapies like chemotherapy. It has been shown to improve immune surveillance, potentially slowing tumor progression and improving survival in models of melanoma, hepatocellular carcinoma, and non-small cell lung cancer.
Infectious Diseases: A major area of investigation is its use against chronic viral infections. Clinical studies have explored Tα1 in hepatitis B and C, where it enhances viral clearance, normalizes liver enzymes, and improves seroconversion rates when combined with antivirals. Research also extends to its potential role in managing sepsis and severe bacterial infections by modulating the dysregulated immune response.
Autoimmune and Inflammatory Conditions: Paradoxically, given its immune-enhancing effects, some research explores Tα1's potential in autoimmune diseases. It appears to exert a regulatory, balancing effect on the immune system, potentially restoring tolerance in conditions like rheumatoid arthritis in preclinical models, though this area requires further investigation.
Safety & Side Effects
Based on data from animal studies and extensive human clinical trials, Thymosin alpha-1 is generally well-tolerated with a favorable safety profile. The most commonly reported side effects in clinical research are mild and localized to the injection site, including erythema, pain, and swelling. Systemic side effects are rare but have included mild fever, fatigue, and headache. No significant organ toxicity has been consistently reported at therapeutic doses. Theoretical concerns exist regarding the potential for exacerbating pre-existing autoimmune conditions due to its immunostimulatory properties, though evidence for this is limited. Anecdotal reports from non-clinical use are scarce but align with the mild profile observed in trials.
Dosage Information
This information is derived from published research studies and is for research purposes only. In clinical research, Thymosin alpha-1 is typically administered via subcutaneous injection. Common research dosing regimens involve 0.9 to 1.6 mg (900 to 1600 mcg), administered twice weekly. Some protocols use daily administration of 0.9 mg for an initial induction period (e.g., 2-4 weeks), followed by a maintenance phase of twice-weekly injections. Treatment duration in studies varies widely, from several weeks for acute conditions to many months or even years for chronic viral infections or as a cancer adjuvant. Intramuscular injection is also a reported route in some studies.
References
Goldstein, A.L., et al. 'Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide.' Proceedings of the National Academy of Sciences, 1977.
Garaci, E., et al. 'Thymosin alpha1 in the treatment of cancer: from basic research to clinical application.' International Journal of Immunopharmacology, 2000.
Sherman, K.E., et al. 'Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.' Journal of Hepatology, 1998.
Tuthill, C., et al. 'Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance.' Annals of the New York Academy of Sciences, 2010.
Romani, L., et al. 'Thymosin alpha1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling.' Blood, 2004.
Camerini, R., & Garaci, E. 'Historical review of thymosin α1 in infectious diseases.' Expert Opinion on Biological Therapy, 2015.